Pfizer Kickback Ruling Shows Drug Copay Program Risks

By Sophia Gaulkin and Alan Kirschenbaum (September 23, 2022, 2:38 PM EDT) -- In a recent decision, the U.S. Court of Appeals for the Second Circuit upheld the U.S. Department of Health and Human Services Office of the Inspector General's position that Pfizer Inc.'s proposed copay assistance program for its high-cost heart treatment would violate the federal Anti-Kickback Statute.[1] In the course of explaining its decision, the court interpreted several aspects of the AKS, including:...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!